Literature DB >> 24524236

A cocoon immunisation strategy against pertussis for infants: does it make sense for Ontario?

G H Lim1, S L Deeks, N S Crowcroft.   

Abstract

Pertussis deaths occur primarily among infants who have not been fully immunised. In Ontario, Canada, an adult booster dose was recently added to the publicly funded immunisation programme. We applied number-needed-to-treat analyses to estimate the number of adults that would need to be vaccinated (NNV) to prevent pertussis disease, hospitalisation and death among infants if a cocoon strategy were implemented. NNV=1/(P(M) X R) + 1/(P(F) X R), where P(M),P(F) (proportion of infants infected by mothers, fathers) were sourced from several studies. Rates of disease, hospitalisation or death (R) were derived from Ontario's reportable disease data and Discharge Abstract Database. After adjusting for under-reporting, the NNV to prevent one case, hospitalisation or death from pertussis was between 500-6,400, 12,000-63,000 and 1.1-12.8 million, respectively. Without adjustment, NNV increased to 5,000-60,000, 55,000-297,000 and 2.5-30.2 million, respectively. Rarer outcomes were associated with higher NNV. These analyses demonstrate the relative inefficiency of a cocoon strategy in Ontario, which has a well-established universal immunisation programme with relatively high coverage and low disease incidence. Other jurisdictions considering a cocoon programme should consider their local epidemiology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24524236     DOI: 10.2807/1560-7917.es2014.19.5.20688

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  8 in total

Review 1.  What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.

Authors:  Shelly Bolotin; Eric T Harvill; Natasha S Crowcroft
Journal:  Pathog Dis       Date:  2015-08-06       Impact factor: 3.166

Review 2.  Vaccines to prevent pneumonia in children - a developing country perspective.

Authors:  Jacquie N Oliwa; Ben J Marais
Journal:  Paediatr Respir Rev       Date:  2015-08-19       Impact factor: 2.726

3.  Randomized clinical trial of the safety and immunogenicity of the Tdap vaccine in pregnant Mexican women.

Authors:  Jesús Zacarías Villarreal Pérez; José Manuel Ramírez Aranda; Manuel de la O Cavazos; Michelle de J Zamudio Osuna; José Perales Dávila; María Romelia Ballesteros Elizondo; Marco Vinicio Gómez Meza; Francisco Javier García Elizondo; Azucena M Rodríguez González
Journal:  Hum Vaccin Immunother       Date:  2017-01-02       Impact factor: 3.452

4.  Risk Factors for Pertussis Among Hispanic Infants: Metropolitan Portland, Oregon, 2010-2012.

Authors:  Kara M Levri; Laura Reynolds; Juventila Liko; Mary Dott; Byron F Robinson; Paul R Cieslak
Journal:  Pediatr Infect Dis J       Date:  2016-05       Impact factor: 2.129

Review 5.  Immunological and Clinical Benefits of Maternal Immunization Against Pertussis: A Systematic Review.

Authors:  Charlotte Switzer; Caroline D'Heilly; Denis Macina
Journal:  Infect Dis Ther       Date:  2019-09-18

Review 6.  Vertically Transferred Immunity in Neonates: Mothers, Mechanisms and Mediators.

Authors:  Marie Albrecht; Petra Clara Arck
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

7.  Risk factors for Bordetella pertussis disease in hospitalized children.

Authors:  Rudzani Muloiwa; Felix S Dube; Mark P Nicol; Gregory D Hussey; Heather J Zar
Journal:  PLoS One       Date:  2020-10-15       Impact factor: 3.240

Review 8.  Emerging macrolide resistance in Bordetella pertussis in mainland China: Findings and warning from the global pertussis initiative.

Authors:  Ye Feng; Cheng-Hsun Chiu; Ulrich Heininger; Daniela Flavia Hozbor; Tina Quanbee Tan; Carl-Heinz Wirsing von König
Journal:  Lancet Reg Health West Pac       Date:  2021-02-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.